Category

Archives

DNA Methyltransferase

Discovery of potent DNMT1 inhibitors against sickle cell disease using structural-based virtual screening, MM-GBSA and molecular dynamics simulation-based approaches

57 views | Jan 25 2024

The study's rigorous virtual screening and molecular dynamics simulations identified promising compounds with potential to inhibit DNMT1, offering a hopeful avenue for improving sickle cell disease treatment pending further in vitro and in vivo validation. [Read the Full Post]

Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma

69 views | Aug 28 2023

The study demonstrated that a dual inhibitor targeting histone methyltransferase G9a and DNA methyltransferases (DNMTs) induced tumor cell cycle arrest, apoptosis, and an IFN-I response, while promoting dendritic cell and T-cell infiltration, ultimately increasing the overall survival of mice with melanoma in combination with TCR-redirected T-cell therapy and dendritic cell vaccination. [Read the Full Post]

Loss of deubiquitylase USP2 triggers development of glioblastoma via TGF-β signaling

91 views | Jun 01 2023

This study suggests that USP2 is a major regulator of the TGF-β signaling pathway in glioblastoma, and its loss leads to poor prognosis in patients, while DNMT3A inhibitor SGI-1027 could be a potential treatment by inducing USP2 expression and suppressing TGF-β signaling. [Read the Full Post]

The Protective Effect of Zebularine, an Inhibitor of DNA Methyltransferase, on Renal Tubulointerstitial Inflammation and Fibrosis

73 views | May 22 2023

Inhibiting DNA methylation can restore the balance between pro-inflammatory and anti-inflammatory pathways, alleviate renal inflammation and fibrosis, and highlight DNA methyltransferases as potential therapeutic targets for treating chronic kidney disease. [Read the Full Post]

FZD7, Regulated by Non-CpG Methylation, Plays an Important Role in Immature Porcine Sertoli Cell Proliferation

74 views | May 22 2023

This study explores the regulatory roles of non-CpG methylation in testicular development, identifying several hub genes such as FZD7, which is found to be important in linking the proliferation and apoptosis of Sertoli cells. [Read the Full Post]

A small-molecule degrader of TET3 as treatment for anorexia nervosa in an animal model

72 views | May 11 2023

Bobcat339, a synthetic small molecule that binds to the catalytic pockets of TET proteins, shows potential as a therapeutic for anorexia nervosa and stress-related disorders by inducing TET3 protein degradation and stimulating the expression of AGRP, NPY, and VGAT in a TET3-dependent manner. [Read the Full Post]

Prelimbic Cortical Stimulation with L-methionine Enhances Cognition through Hippocampal DNA Methylation and Neuroplasticity Mechanisms

65 views | Apr 07 2023

The study suggests that targeting hippocampal DNA methyltransferase (DNMT) through prelimbic cortical deep brain stimulation (PrL DBS) and L-methionine (MET) co-administration may enhance memory and serve as a potential therapeutic approach for treating dementia. [Read the Full Post]

Development and Optimisation of Inhalable EGCG Nano-Liposomes as a Potential Treatment for Pulmonary Arterial Hypertension by Implementation of the Design of Experiments Approach

229 views | Mar 21 2023

The research developed an inhalable EGCG nano-liposome formulation with desirable properties and demonstrated its potential effectiveness in treating PAH by inhibiting the TGFβ pathway. [Read the Full Post]

Clinical Characteristics and Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

150 views | Mar 08 2023

Blastic plasmacytoid dendritic cell neoplasm is a rare and aggressive hematological malignancy with diverse clinical manifestations and poor prognosis that requires a combination of clinical, morphological and immunophenotypic features for diagnosis and individualized treatment. [Read the Full Post]

Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy

168 views | Mar 07 2023

The phase I/II trial showed that cusatuzumab plus azacitidine was generally well-tolerated and showed preliminary efficacy in newly diagnosed AML patients ineligible for intensive chemotherapy, with ongoing investigation into the combination with venetoclax and azacitidine. [Read the Full Post]